Pope B D,Gilbert D M. Genetics:Up and down in Down’s syndrome[J]. Nature,2014,508(7496):323-324.？ [2]Roizen N J,Patterson D. Down’s syndrome[J]. Lancet,2003,361(9365): 1281-1289.？ [3]Kamalakar A,Harris J R,McKelvey K D, et al. Aneuploidy and Skeletal Health[J]. Curr Osteoporos Rep,2014,12(3): 376-382.？ [4]蒋滢,张波,李维,等. 早期诊断唐氏综合征的母体血清蛋白新标志物筛选与初步验证[J]. 中华检验医学杂志,2012,35(4): 328-332.？ [5]Gorg A,Obermaier C,Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients[J]. Electrophoresis,2000,21(6): 1037-1053.？ [6]Yan J X,Wait R,Berkelman T, et al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry[J]. Electrophoresis,2000,21(17):3666-3672.？ [7]Klase Z A,Van-Duyne R,Kashanchi F. Identification of potential drug targets using genomics and proteomics:a systems approach[J]. Adv Pharmacol,2008,56: 327-368.？ [8]Tabor A,Philip J,Madsen M, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women[J]. Lancet,1986,1(8493): 1287-1293.？ [9]Nicolaides K H. Screening for fetal aneuploidies at 11 to 13 weeks[J]. Prenat Diagn,2011,31(1): 7-15. [10]Malone F D,Canick J A,Ball R H, et al. First-trimester or second-trimester screening,or both,for Down’s syndrome[J]. N Engl J Med,2005,353(19): 2001-2011.？ [11]Ehrich M,Deciu C,Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood:a study in a clinical setting[J]. Am J Obstet Gynecol,2011,204(3): 205.e1-205.e11.？ [12]Song K,Musci T J,Caughey A B. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population[J]. J Matern Fetal Neonatal Med,2013,26(12): 1180-1185.？ [13]Benn P,Cuckle H,Pergament E. Non-invasive prenatal testing for aneuploidy:current status and future prospects[J]. Ultrasound Obstet Gynecol,2013,42(1):15-33.？ [14]Yamamoto R,Ohkouchi T,Tabata K, et al. A study of oligosaccharide variants of alpha-fetoproteins produced by normal fetuses and fetuses with trisomy 21[J]. Acta Obstet Gynecol Scand,2005,84(12):1145-1149.？ [15]Wenstrom K D. Evaluation of Down syndrome screening strategies[J]. Semin Perinatol,2005,29(4): 219-224.？ [16]Nagalla S R,Canick J A,Jacob T, et al. Proteomic analysis of maternal serum in down syndrome:identification of novel protein biomarkers[J]. J Proteome Res,2007,6(4):1245-1257.？ [17]Yu B,Zhang B,Wang J, et al. Preliminary proteomic-based identification of a novel protein for Down’s syndrome in maternal serum[J]. Exp Biol Med (Maywood),2012,237(5):530-539.？ [18]Heywood W,Mills K,Wang D, et al. Identification of new biomarkers for Down’s syndrome in maternal plasma[J]. J Proteomics,2012,75(9): 2621-2628.？ [19]Kolla V,Jeno P,Moes S, et al. Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ) [J]. J Biomed Biotechnol,2010,2010: 952047.？ [20]Hellwage J,Jokiranta T S,Koistinen V, et al. Functional properties of complement factor H-related proteins FHR-3 and FHR-4:binding to the C3d region of C3b and differential regulation by heparin[J]. FEBS Lett,1999,462(3):345-352.？ [21]Lalmanach G,Naudin C,Lecaille F, et al. Kininogens:More than cysteine protease inhibitors and kinin precursors[J]. Biochimie,2010,92(11): 1568-1579.？ [22]Sun D,McCrae K R. Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species[J]. Blood,2006,107(12):4714-4720. ？
